specific siRNA in pancreatic cancer: a phase I study with immunological correlates

Nature·Sep 30

This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Pancreatic Cancer: Extended Release siRNA Implant Targeting KRAS Shows Promising Improvement Trends in Survival and Response in Select Patients

Memorial Sloan Kettering Cancer Center·Jan 29

2

iEXPLORE Phase I Trial: Engineered Exosomes with KRASG12D siRNA in Pancreatic Cancer

Oncodaily·Oct 3

3

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

GlobeNewswire·Apr 28

4

Silexion Completes SIL204 Toxicology for Pancreatic Cancer

The Clinical Trial Vanguard·Nov 29

5

Direct pulmonary delivery route in lung cancer: a highway for siRNA therapeutics

Frontiers·Dec 15

6

Non-cationic carriers for siRNA delivery: Current progress and potential applications

ScienceDirect.com·Dec 10

7

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Nature·Nov 28

8

Raghu Kalluri: First-in-Human Trial of Exosomes Targeting KRAS G12D in Pancreatic Cancer

Oncodaily·Oct 2